Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Chugai Sales Climb 9.6%, Actemra Sales Exceed 100 Billion Yen
February 3, 2014
- Sanofi Demands Payment of $416 Million from Novartis over Dissolved Equa Deal
January 31, 2014
- Novartis Suspected of Drafting Conference Presentation Materials on “Sign” Trial
January 31, 2014
- Novartis Global Net Profit Falls 1%, Japan Sales Drop 15.8%
January 31, 2014
- Maruho to Acquire Distribution Rights for Atopic Dermatitis Drug Protopic from Astellas
January 31, 2014
- Sawai, Nichi-Iko Boosting Annual Production Capacity to 10 Billion Tablets Each in Anticipation of Future Market Growth
January 31, 2014
- Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
- Sosei Transfers NorLevo MA Rights to ASKA
January 30, 2014
- Mochida Eyes 10 Billion Yen Generic Biz, Valsartan Combination Drug to Debut in 2014: Pres.
January 29, 2014
- Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
- Lurasidone Receives CHMP Positive Opinion: DSP, Takeda
January 29, 2014
- Kenko.com Sues Government over Restriction of Online OTC Drug Sales
January 28, 2014
- Asano Named as New Asahi Kasei President
January 28, 2014
- Zydus to Withdraw from Japan, Discontinuing Shipments by March-End Due to Policy Change of Parent Company
January 28, 2014
- Ajinomoto to Downsize In-House Drug Discovery Research amid Slack Pharma Biz
January 27, 2014
- BioWa Out-Licenses Kyowa Hakko Kirin’s Technologies and Serves as Its “In-Licensing Window”; “Naked” Mabs to Remain Dominant until 2002
January 27, 2014
- Sanwa Kagaku, Dong-A ST of South Korea Sign License Deal for Nesp Biosimilar in Japan
January 27, 2014
- Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting
January 24, 2014
- Antidepressant Brintellix Launched in US: Takeda, Lundbeck
January 24, 2014
- Novartis Adds LABA/LAMA Combination Ultibro to Lineup of Breezhaler Products for COPD Using the Same Inhaler
January 24, 2014
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…